Analysed Viatris Inc (VTRS:NASDAQ) News Sources
U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma
Le Lézard
Halozyme Therapeutics, Inc.: U.S. FDA Approves TECVAYLI in Combination with DARZALEX FASPRO for Relapsed/Refractory Multiple Myeloma
FinanzNachrichten.de
Theravance Biopharma, Inc.: Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction ...
FinanzNachrichten.de
Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates
Markets Insider
What is the current price of Viatris Inc (VTRS:NASDAQ)?
The current price of Viatris Inc (VTRS:NASDAQ) is $14.16.
Viatris Inc (VTRS:NASDAQ) absolute price change since previous trading day?
The absolute price change of Viatris Inc (VTRS:NASDAQ) since the previous trading day is $-0.37.
Viatris Inc (VTRS:NASDAQ) percentage price change since previous trading day?
The percentage price change of Viatris Inc (VTRS:NASDAQ) since the previous trading day is -2.55%.
What is This Week's average sentiment score for Viatris Inc (VTRS:NASDAQ)?
This Week's average sentiment score for Viatris Inc (VTRS:NASDAQ) is 70 out of 100.
What is This Week's average sentiment for Viatris Inc (VTRS:NASDAQ)?
This Week's sentiment for Viatris Inc (VTRS:NASDAQ) is .
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.